Clinical Trial Update: Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma [NA]

View source ↗

Summary

Update on an ongoing study evaluating gemcitabine, nab-paclitaxel, PEGPH20, and rivaroxaban in advanced pancreatic ductal adenocarcinoma; the trial is active bu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• Gemzar (gemcitabine)
• PEGPH20 (pegylated hyaluronidase)
• Xarelto (rivaroxaban)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Pancreatic Cancer, Advanced Pancreatic Ductal Adenocarcinoma | NA | Status: ACTIVE_NOT_RECRUITING